title: Using pharmacogenetics in real time to guide warfarin initiation: a clinician update.
authors.affiliation: Intermountain Medical Center, Cardiovascular Department, 5121 S. Cottonwood Street, Murray, UT 84107-5701, USA.
authors.forename: John F
authors.initials: JF
authors.lastname: Carlquist
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Anderson
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics; D001281:Atrial Fibrillation / Q000150:complications* / Q000235:genetics; D065729:Cytochrome P-450 CYP2C9; D005260:Female; D006801:Humans; D006899:Mixed Function Oxygenases / Q000235:genetics; D010597:Pharmacogenetics / Q000379:methods*; D057285:Precision Medicine / Q000379:methods; D013927:Thrombosis / Q000235:genetics / Q000517:prevention & control*; D064417:Vitamin K Epoxide Reductases; D014859:Warfarin / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000925:Anticoagulants; D014859:Warfarin; D006899:Mixed Function Oxygenases; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D064417:Vitamin K Epoxide Reductases